Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia.
Publication/Presentation Date
2-1-2011
Abstract
α-Synuclein is a key component of the Lewy body, a large globular protein complex that forms in the nervous system of patients with Parkinson disease and other dementias [1-3]. Since α-synuclein also occurs in megakaryocytic and erythroid lineages [4-7], we wondered what role synucleins had in the hematopoietic system. Therefore, we studied the expression of α-, β-, and γ-synucleins in a comprehensive panel of patient bone marrows and leukemic cell lines. We observed under expression of α-synuclein in the megakaryocytes of myeloproliferative neoplasm (MPN), but not normal reactive marrow (NRM) or myelodysplastic syndrome (MDS). Conversely, we observed over expression of β-synuclein in the blasts of megakaryoblastic leukemias (MegL), but not acute myeloid leukemia (AML) or erythroleukemia (EryL), suggesting that α- and β-synucleins could be useful adjunct markers for the early detection of MDS and the differential diagnosis of EryL and MegL from other AMLs.
Volume
86
Issue
2
First Page
230
Last Page
234
ISSN
1096-8652
Published In/Presented At
Maitta, R. W., Wolgast, L. R., Wang, Q., Zhang, H., Bhattacharyya, P., Gong, J. Z., Sunkara, J., Albanese, J. M., Pizzolo, J. G., Cannizzaro, L. A., Ramesh, K. H., & Ratech, H. (2011). Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. American journal of hematology, 86(2), 230–234. https://doi.org/10.1002/ajh.21932
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
21264917
Department(s)
Administration and Leadership
Document Type
Article